First-line screening logic to identify patients who require biochemical testing for Pheochromocytoma or Paraganglioma. Trigger when a clinician asks "who to screen for pheo", "evaluation of adrenal incidentaloma", or "workup for paroxysmal hypertension."
Scanned 9/9/2026
Install to Claude Code
npx -y skills add dromlakhani/MD2SKILL --skill pheo-screening-strategy --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Pheo Screening Strategy?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-pheo-screening-strategy)More formats (shields.io, HTML) on the badges page.
---
name: pheo-screening-strategy
description: First-line screening logic to identify patients who require biochemical testing for Pheochromocytoma or Paraganglioma. Trigger when a clinician asks "who to screen for pheo", "evaluation of adrenal incidentaloma", or "workup for paroxysmal hypertension."
---
# Pheochromocytoma Screening Strategy
This skill provides the clinical decision criteria for initiating biochemical screening for pheochromocytoma and paraganglioma based on the Endocrine Society Clinical Practice Guidelines.
---
## Step 1 — Identification of High-Risk Clinical Features
Screen for pheochromocytoma if **any** of the following are present:
1. **Paroxysmal Symptoms ("The Spell"):**
- Triad of: Episodic headache, sweating, and palpitations.
- Note: The presence of all three in a hypertensive patient has high specificity (>90%).
2. **Refractory or Early-Onset Hypertension:**
- Drug-resistant hypertension (uncontrolled on ≥3 agents).
- Marked blood glucose lability or paradoxically worsening BP with beta-blockers.
- Hypertension onset at age <20 years.
3. **Adrenal Incidentaloma:**
- Any adrenal mass discovered on imaging, especially if the unenhanced CT attenuation is >10 Hounsfield Units (HU).
4. **Genetic Predisposition:**
- Personal or family history of MEN2, NF1, or von Hippel-Lindau (VHL).
- Personal history of a previous glomus tumor or paraganglioma.
---
## Step 2 — Decision: To Screen or Not to Screen?
| Finding Present? | Action |
|---|---|
| **YES** to any above | Move to **Biochemical Testing** (Plasma or 24h Urinary Metanephrines). |
| **NO** | Pheochromocytoma is unlikely; manage as primary hypertension unless other secondary features emerge. |
---
## Clinical Guardrails
- **Do NOT proceed to imaging first.** Always obtain biochemical proof before ordering CT or MRI. Imaging first leads to false positives and unnecessary surgeries.
- **Beta-Blocker Warning:** Never start a beta-blocker (e.g., Propranolol, Atenolol) before establishing alpha-blockade if pheo is suspected, as this can trigger a hypertensive crisis due to unopposed alpha-stimulation.
- **Medication Interference:** Many drugs (TCAs, Levodopa, Decongestants) can cause false-positive metanephrine elevations. Review the med list before testing.
---
**Source:** Lenders JW, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2014;99(6):1915-42. doi: 10.1210/jc.2014-1498
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!